Recent progress in fluorine-18 labelled peptide radiopharmaceuticals

European Journal of Nuclear Medicine

Volumn 28, Issue 7, 2001, Pages 929-938

  Okarvi, S M ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Fluorine 18; Peptide radiopharmaceuticals; Positron emission tomography; Radiofluorination

Indexed keywords

FLUORINE 18; PEPTIDE; RADIOPHARMACEUTICAL AGENT;

DIAGNOSTIC IMAGING; DRUG RECEPTOR BINDING; ISOTOPE LABELING; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; REVIEW;

ANIMALS; FLUORINE RADIOISOTOPES; HUMANS; RADIOPHARMACEUTICALS;

EID: 0034911579     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590100508     Document Type: Review

References (65)

1. m-labelled peptide-based radiopharmaceuticals: An overview
2. A comparative study of N.C.A. fluorine-18 labeling of proteins via acylation and photochemical conjugation
3. A ticket to ride: Peptide radiopharmaceuticals
4. From monoclonal antibodies to peptides and molecular recognition units: An overview
5. Peptide radiopharmaceuticals in nuclear medicine
6. 99mTc-aquation labels peptide to an unprecedented high specific activity
7. Radio-labeled receptor-binding peptides: A new class of radiopharmaceuticals
8. 18F labelling of proteins
9. 99mTc
10. Radiolabeled peptides and other ligands for receptors overexpressed in tumor cells for imaging neoplasms
11. Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody
12. 18F-labeled radiopharmaceuticals for PET in oncology, excluding FDG
13. Fluorine-18 labeled receptor based radiopharmaceuticals
14. Synthesis of a carbon-11 labeled substance P receptor ligand for PET studies
15. 11C]substance P
16. Application of silicon-fluoride chemistry to fluorine-18 labeling agents for biomolecules: A preliminary note
17. 1)-octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: Synthesis, radiolabeling, in vitro validation and biodistribution in mice
18. 18F]fluorobenzoyl octreotide and biodistribution in tumour-bearing Lewis rats
19. 86Y-DTPA-octreotide
20. 7]-α-MSH, an α-melanocyte stimulating hormone analogue
21. Fluorine-18 labeled chemotactic peptides: A potential approach for the PET imaging of bacterial infection
22. Fluorine-18 labeling of proteins
23. Is there a future for clinical fluorine-18 radio-pharmaceuticals (excluding FDG)?
24. Radiohalogenation of proteins: An overview of radionuclides, labeling methods, and reagents for conjugate labeling
25. Positron emission tomography (PET) methodology for small animals and its application in radiopharmaceutical preclinical investigation
26. 186/188Re radiopharmaceuticals
27. Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates
28. Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies
29. 18F]-N-succinimidyl 4-(fluoromethyl)benzoate for protein labeling
30. 18F](fluoromethyl)benzoate
31. 18F]fluorocarboxylic acids
32. Recommendations for fluorine-18 production
33. First direct fluorination of tyrosine-containing biologically active peptides
34. A prosthetic group for the rapid introduction of fluorine into peptides and functionalized drugs
35. 18F-labeled insulin: A prosthetic group methodology for incorporation of a positron emitter into peptides and proteins
36. 18F]arylnitrene
37. Fluorine-18-labeled monoclonal antibody fragments: A potential approach for combining radioimmunoscintigraphy and positron emission tomography
38. F-18 labelling and in vitro evaluation of BQ3020, the first PET ligand synthesised for the endothelin receptor
39. 18F]fluorobenzoate and its application to the labeling of a monoclonal antibody fragment
40. 18F]fluorobenzoate
41. Formation of carboxamides with N,N,N′,N′-tetramethyl(succinimido)uronium tetrafluoroborate in aqueous/organic solvent systems
42. Improved method for preparing N-hydroxysuccinimide ester-containing polymers for affinity chromatography
43. 18F-labelled neurotensin(8-13) analogs for positron emission tomography (PET): Pharmacological and biochemical characterisation
44. Fluorine-18 labelling of neurotensin analogues for the development of tumour imaging agents
45. 3 integrin expression
46. 88/90Y]yttrium
47. 18F]-labelled linear peptides
48. 18F]labelled peptides using a solid phase methodology
49. 18F]fluorobenzoate
50. 18F-labeled insulin and positron emission tomography
51. Synthesis of fluorine-18 labeled biotin derivatives: Biodistribution and infection localization
52. Fluorine-18 labeling of monoclonal antibodies and fragments with preservation of immunoreactivity
53. 2 fragment in a subcutaneous xenograft model
54. 2 fragment in normal dogs
55. PET imaging of osteosarcoma in dogs using a fluorine-18-labeled monoclonal antibody Fab fragment
56. Fluorine-18 labelling of oligonucleotides bearing chemically-modified ribose-phosphate backbones
57. A general method to label antisense oligonucleotides for pharmacological and imaging studies
58. In vivo imaging of oligonucleotides
59. 18F-fluoroacylation via fluorocarboxylic acid esters
60. 18F-Fluoroacetate an agent for introducing no-carrier-added fluorine-18 into urokinase without loss of biological activity
61. 18F]fluorocarboxylic acids
62. 18F
63. In vivo evaluation of fluorine-18 labelled human proinsulin connecting peptide (C-peptide) in monkey using PET
64. Labelling and preliminary in vitro evaluation of the vasoactive peptide ET-1, a PET radioligand for the endothelin receptor
65. 18F]-BQ3020, a PET radioligand for the endothelin-B receptor